Oliver Pfaar

European of German nationality. Professor, ORL and allergist, @EAACI ExCom member, DGAKI ext. board of directors. Associate Editor Allergy

[Oliver Pfaar @OPfaar]

no longer on X (former Twitter).

Reach me though: https://t.co/VE8tUUtXSZ

or EMail: [email protected]

[Oliver Pfaar @OPfaar]

published in Allergy today: 'How does allergen immunotherapy-induced tolerance improve the airway epithelial barrier function: A mechanistical-driven hypothesis.' (Pfaar et al. Allergy. 2023 Aug 6. doi: 10.1111/all.15835)

https://t.co/PVQfXlyEmy

as always: Read/Enjoy/Share

[Oliver Pfaar @OPfaar]

For experts and stakeholders in AIT-research:
EAACI Task-Force Position Paper on 'Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma'

Read/Enjoy/Share.
Best, Oliver

https://t.co/M00yTKgEkP

[Oliver Pfaar @OPfaar]

Very recently published in WAO from our US- and EU-expert network:

Comparison of allergen immunotherapy practice patterns in inhalant allergies in the US and Europe: Similarities and differences 2023:

Unmet needs of AIT!
Read/Enjoy/Share. Thanks, Oliver

https://t.co/wUPR8GmcES

[Oliver Pfaar @OPfaar]

EAACI congress 2023

…so great to meet both KOLs and friends again!

[Oliver Pfaar @OPfaar]

On my way to Hamburg, Germany: Annual EAACI congress 2023: excited to meet so many colleagues and friends again. 4 days long !!!
Find me in the programme: great to have you in the rooms or remote. Oliver

[Oliver Pfaar @OPfaar]

Berlin, 24.Mai : 
16. Runder Tisch Allergologie 
Wichtige berufspolitische Akzente mit gesundheitspolitischen Sprecher*innen des Deutschen Bundestages, GKV-Spitzenverbänden und Industrie:

klarer Auftrag: PRO Allergologie und AIT !!!

[Oliver Pfaar @OPfaar]

Just published from our group: read/enjoy/share. Thank you, Oliver "Improvement of daily allergy control by sublingual immunotherapy: A MASK-air® study" (via #pubmedontap) https://t.co/MK5yULXTN7

[Oliver Pfaar @OPfaar]

@MichaOrdak @i_yakoub_agha @_atanas_ @EmmaGuttman @sminaev2015 @ScienceCommuni2 @TheLancet @EAACI_HQ @WAME_editors @PinkasJJ Wonderful! Congrats 👍

[Allergy EAACI @AllergyEaaci]

Open Access: Adherence and persistence in allergen immunotherapy (APAIT): a reporting checklist for retrospective studies. First and corresponding author: Oliver Pfaar

Read the article here: https://t.co/ACb3TPoHv8

The understanding of adherence or persistence to allergen immunotherapy (AIT) is hampered by a lack of specific guidance on appropriate clinical trial design. Pfaar et al. conducted a comprehensive review of current evidence and developed a checklist to enhance the design and reporting of trials evaluating adherence or persistence to AIT. The APAIT checklist is novel and highlights an important issue in the allergy field.

Read more articles published in #Allergy on allergen #immunotherapy here: https://t.co/Lskxt3aRXa

#Allergy_journal @OPfaar

[Oliver Pfaar @OPfaar]

für Patient*innen mit einer schweren Form der chronischen Nasennebenhöhlenentzündung mit Polypen (#CRSwNP): nehmen Sie gerne gleich mit uns Kontakt auf:

Tel.: [phone]
EMail: [email protected]

Wir freuen uns auf Ihre Kontaktaufnahme👍!
Prof.Pfaar & Team

[Oliver Pfaar @OPfaar]

published (27 Mar 2023) & open access from our group:

"Adherence and persistence in allergen immunotherapy (APAIT): a reporting checklist for retrospective studies"

https://t.co/151osnZSWI

[Oliver Pfaar @OPfaar]

jetzt online: "Therapie der chronischen Rhinosinusitis mit Polyposis nasi (CRScNP) mit monoklonalen Antikörpern (Biologika)"

>> S2k-LL nach AWMF-Regelwerk samt Dokumentationsbogen und Evidenztabellen

https://t.co/criH0DSDmW

[Oliver Pfaar @OPfaar]

STERN Ärzteliste „Allergien“ 2023

https://t.co/0Z8JuQSsgU

[Oliver Pfaar @OPfaar]

TV-Bericht über CRSwNP und Biologika:
Nicht nur für Patienten interessant (sondern auch für Eintracht-Fans😀):

https://t.co/FYV9oySv36

[Oliver Pfaar @OPfaar]

Important reading: published today:

AIT 111 years (part-2): also free access to all articles via Pubmed.

https://t.co/8c1vCTW3FU

[EAACI @EAACI_HQ]

Watch this message from @OPfaar - EAACI Congress Ambassador.
Join us in Hamburg for the #EAACICongress2023 , an event that will offer the latest scientific breakthroughs, networking opportunities and countless possibilities to transform healthcare.
➡️https://t.co/SQ8iwaZxID

[Oliver Pfaar @OPfaar]

Live from Dresden: AG Allergologie (DG HNO-KHC): meeting friends and top-experts in Rhinology

[Oliver Pfaar @OPfaar]

für meine Patientinnen und Patienten: bitte Termin vormerken !

DigiPat '23: TYP-2-Entzündungen, Asthma, Allergie auf Zahnmaterialien, Pollenallergie, Allergien auf Tierhaare, Anaphylaxie https://t.co/JkG03QKvmT